Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biovica International publ : strengthens with new R&D Director

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/15/2019 | 02:01am EST

Uppsala, November 15, 2019. Biovica, active in cancer diagnostics, today announced that Otti Bengtsson Gref has been appointed new R&D Director and will be part of the management team. She most recently comes from the role as R&D Director at Cavidi.

Otti Bengtsson Gref has a long experience of leading positions in the R&D field in the commercial diagnostic industry. Otti most recently comes from the role as R&D Director at Cavidi. She has held various managerial positions in R&D at IDD, Thermo Fisher Scientific from 2010 to 2018, and before that, from 2003 to 2010, she was a specialist, product manager and finally head of Product Management at Phadia. Otti Bengtsson Gref is Med. Lic in Immunology and also holds an Executive MBA. She will take up her position as R&D Director on January 7, 2020.

"I look forward to start working for Biovica and DiviTum. I am impressed by how far the company has come in developing the product, collaborations with leading oncologists and the results that have come from these collaborations. I look forward to contributing to the approval of DiviTum so that it can be used to contribute to better treatment for cancer patients in the world," says Otti Bengtsson Gref.

"We are very pleased to have recruited Otti as new head of R&D. Her expertise and her experience in developing diagnostic products that have gone through regulatory approval and commercialization make her ideal for Biovica. We look forward to having Otti in the team as we continue to develop Biovica's market expansion and take DiviTum to the market for the benefit of patients and society," says Anders Rylander, CEO of Biovica.

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

Biovica - Best Treatment from Day One.
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-strengthens-with-new-r-d-director,c2962165

https://mb.cision.com/Main/14910/2962165/1141713.pdf

https://news.cision.com/biovica-international-ab/i/bw-ottibengtssongref,c2716337

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOVICA INTERNATIONAL AB (
12/06BIOVICA INTERNATIONAL PUBL : strengthens management team
AQ
12/05Q2 INTERIM REPORT : Work with the FDA application progressing as planned
PU
12/05Q2 INTERIM REPORT :  Work with the FDA application progressing as planned
AQ
11/20BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
PU
11/20BIOVICA INTERNATIONAL PUBL : DiviTum - Strong prognostic marker in operable brea..
AQ
11/20BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
AQ
11/15BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
AQ
10/25BIOVICA ISO 13485 : 2016 certificate renewal
AQ
10/03BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
AQ
09/18BIOVICA INTERNATIONAL : DiviTum® Included in New U.S. Cancer Study
AQ
More news
Financials (SEK)
Sales 2020 4,60 M
EBIT 2020 -29,0 M
Net income 2020 -36,0 M
Finance 2020 26,0 M
Yield 2020 -
P/E ratio 2020 -7,27x
P/E ratio 2021 -50,9x
EV / Sales2020 51,7x
EV / Sales2021 11,7x
Capitalization 264 M
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 23,10  SEK
Last Close Price 11,20  SEK
Spread / Highest target 106%
Spread / Average Target 106%
Spread / Lowest Target 106%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOVICA INTERNATIONAL AB (PUBL)34.52%28
GUARDANT HEALTH, INC.96.81%6 947
GENSCRIPT BIOTECH CORPORATION87.81%4 694
IOVANCE BIOTHERAPEUTICS, INC.179.32%3 120
INVITAE CORPORATION59.95%1 707
VERACYTE, INC.131.96%1 425